Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%

Biofrontera Inc.

Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.
New earnout structure: 12% of net sales up to $65M, 15% above; replaces prior 25-35% perpetual payment.
Closing released final $2.5M of $11M financing led by existing investors Rosalind Advisors and AIGH.
Biofrontera AG receives 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.
Company expects full asset and personnel transfer by late Q4 2025 or early Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.